Our Pipeline

We’re focused on the innovative application of science and medicine

With patients at the center of everything we do, Sunovion has charted new paths to life-transforming treatments that reflect our ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurologic and respiratory disorders.

Candidate Indication/Target Phase
SUN-101/eFlow® Chronic obstructive pulmonary disease (COPD) Registration
Latuda Pediatric and adolescent bipolar depression Phase 3
Dasotraline ADHD, adults Phase 3
Dasotraline ADHD, pediatrics Phase 3
Dasotraline Binge eating disorder, adults Phase 3
APL-130277 OFF episodes associated with Parkinson’s disease Phase 3
SB-623 Chronic stroke Phase 2
SEP-856 Schizophrenia Phase 2
SEP-856 Parkinson’s disease psychosis Phase 2
DSP-6745 Parkinsons disease psychosis Phase 1
DSP-2230 Neuropathic pain Phase 1
DSP-3748 Cognitive impairment associated with schizophrenia Phase 1
WT-2725 Hematologic and solid cancer Phase 1
DSP-1200 Treatment-resistant depression Phase 1